BC Innovations | Aug 6, 2015
Product R&D

Impede a fever

A team at the Massachusetts Institute of Technology has developed an antibody that could treat dengue infections caused by all four serotypes of the virus, and might be able to prevent the disease as well....
BC Week In Review | Nov 10, 2014
Financial News

NanoViricides financial update

NanoViricides Inc. (NYSE-M:NNVC), West Haven, Conn.   Business: Infectious   Date announced: 2014-10-31   Note: NanoViricides filed a shelf registration covering the sale of up to $50 million of its securities. The company, which closed...
BC Innovations | Sep 25, 2014
Cover Story

Interrupting Ebola

The 2014 Ebola outbreak is the largest in the disease's history and the first in West Africa, where it has reached multiple countries. Although an approved therapy looks far away, five of seven patients given...
BC Week In Review | Sep 15, 2014
Financial News

NanoViricides completes warrant exercise

NanoViricides Inc. (NYSE-M:NNVC), West Haven, Conn.   Business: Infectious   Date completed: 2014-09-08   Type: Warrant exercise   Raised: $7.5 million   Shares: 2.1 million   Price: $3.50   Shares after offering: 56.8 million  ...
BioCentury | Sep 15, 2014
Product Development

Ebola realities

Hope that experimental Ebola vaccines and therapies might help contain the current outbreak is sliding into hype as public health officials exaggerate how quickly new products could be deployed and minimize the uncertainties inherent in...
BioCentury | Aug 11, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) was up $0.44 to $22.47 last week after submitting a BLA to FDA for Anthrax immune globulin IV (AIGIV) to treat inhaled anthrax. AIGIV is being developed...
BC Week In Review | Mar 10, 2014
Company News

NanoViricides infectious news

Infectious disease company NanoViricides denied a rumor from a blog post on investment news website Seeking Alpha that the company is being acquired for up to $4.5 billion. In a statement, NanoViricides said it has...
BC Week In Review | Jan 27, 2014
Financial News

NanoViricides completes direct public offering

NanoViricides Inc. (NYSE-M:NNVC), West Haven, Conn.   Business: Infectious   Date completed: 1/21/14   Type: Direct public offering   Raised: $20 million   Units: 3.8 million   Price: $5.25 (unit)   Shares after offering: 53.9...
BioCentury | Jan 27, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones AB Science S.A. (Euronext:AB) fell €2.95 (21%) to €11.36 on Friday after EMA's CHMP recommended against approval of Masiviera masitinib for first-line treatment of non-resectable locally advanced or metastatic pancreatic cancer in combination...
BC Extra | Jan 22, 2014
Financial News

NanoViricides raises $20 million in direct offering

NanoViricides Inc. (NYSE-M:NNVC) raised about $20 million through the sale of about 3.8 million units at $5.25 in a registered direct offering to institutional and existing investors. Each unit comprises a share and a five-year...
Items per page:
1 - 10 of 56
BC Innovations | Aug 6, 2015
Product R&D

Impede a fever

A team at the Massachusetts Institute of Technology has developed an antibody that could treat dengue infections caused by all four serotypes of the virus, and might be able to prevent the disease as well....
BC Week In Review | Nov 10, 2014
Financial News

NanoViricides financial update

NanoViricides Inc. (NYSE-M:NNVC), West Haven, Conn.   Business: Infectious   Date announced: 2014-10-31   Note: NanoViricides filed a shelf registration covering the sale of up to $50 million of its securities. The company, which closed...
BC Innovations | Sep 25, 2014
Cover Story

Interrupting Ebola

The 2014 Ebola outbreak is the largest in the disease's history and the first in West Africa, where it has reached multiple countries. Although an approved therapy looks far away, five of seven patients given...
BC Week In Review | Sep 15, 2014
Financial News

NanoViricides completes warrant exercise

NanoViricides Inc. (NYSE-M:NNVC), West Haven, Conn.   Business: Infectious   Date completed: 2014-09-08   Type: Warrant exercise   Raised: $7.5 million   Shares: 2.1 million   Price: $3.50   Shares after offering: 56.8 million  ...
BioCentury | Sep 15, 2014
Product Development

Ebola realities

Hope that experimental Ebola vaccines and therapies might help contain the current outbreak is sliding into hype as public health officials exaggerate how quickly new products could be deployed and minimize the uncertainties inherent in...
BioCentury | Aug 11, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) was up $0.44 to $22.47 last week after submitting a BLA to FDA for Anthrax immune globulin IV (AIGIV) to treat inhaled anthrax. AIGIV is being developed...
BC Week In Review | Mar 10, 2014
Company News

NanoViricides infectious news

Infectious disease company NanoViricides denied a rumor from a blog post on investment news website Seeking Alpha that the company is being acquired for up to $4.5 billion. In a statement, NanoViricides said it has...
BC Week In Review | Jan 27, 2014
Financial News

NanoViricides completes direct public offering

NanoViricides Inc. (NYSE-M:NNVC), West Haven, Conn.   Business: Infectious   Date completed: 1/21/14   Type: Direct public offering   Raised: $20 million   Units: 3.8 million   Price: $5.25 (unit)   Shares after offering: 53.9...
BioCentury | Jan 27, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones AB Science S.A. (Euronext:AB) fell €2.95 (21%) to €11.36 on Friday after EMA's CHMP recommended against approval of Masiviera masitinib for first-line treatment of non-resectable locally advanced or metastatic pancreatic cancer in combination...
BC Extra | Jan 22, 2014
Financial News

NanoViricides raises $20 million in direct offering

NanoViricides Inc. (NYSE-M:NNVC) raised about $20 million through the sale of about 3.8 million units at $5.25 in a registered direct offering to institutional and existing investors. Each unit comprises a share and a five-year...
Items per page:
1 - 10 of 56